MedTrace Logo

A Study of AL2846 Capsule Combined With Standard Chemotherapy Regimen in Subjects With Advanced Colorectal Cancer

NCT04337879 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2020-07-21

No results posted yet for this study

Summary

This is a study to explore the safety, tolerance and efficacy of AL2846 capsules combined with mFOLFOLX6 or FOLFIRI standard chemotherapy regimen in subjects with advanced metastatic colorectal cancer.

Conditions

  • Advanced Colorectal Cancer

Interventions

DRUG

AL2846

AL2846 is a multi-target receptor tyrosine kinase inhibitor, which has obvious selectivity for c-met.

DRUG

Calcium folate

Calcium folate 400mg/ ㎡ IV on day 1,15 in 28-day cycle

DRUG

5-FU

5-FU 2800mg/ ㎡ IV on day 1, 2, 15, 16 days in 28-day cycle.

DRUG

Oxaliplatin

Oxaliplatin 85mg/ ㎡ administered intravenously (IV) on day 1, day 15 in 28-day cycle.

DRUG

Irinotecan

Irinotecan 180mg/㎡ administered intravenously (IV) on day 1,15 in 28-day cycle.

Sponsors & Collaborators

  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-20
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • China

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04337879 on ClinicalTrials.gov